Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VHHMHCII-MOG-DEX
- Development stage
- Preclinical
- Lead developer
- Cerberus Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
VHHMHCII-MOG-DEX is a preclinical trimodal nanobody-peptide-drug conjugate designed to induce antigen-specific tolerance for the treatment of multiple sclerosis (MS). The therapeutic construct consists of an alpaca-derived single-domain antibody fragment (nanobody) targeting major histocompatibility complex class II (MHCII) antigens, which is site-specifically conjugated at its C-terminus to a myelin oligodendrocyte glycoprotein (MOG) peptide (specifically MOG35-55) and the anti-inflammatory corticosteroid dexamethasone (DEX). By targeting MHCII, the conjugate selectively delivers the autoantigen and dexamethasone to professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells under non-inflammatory conditions. This targeted delivery promotes the deletion, anergy, and regulatory differentiation of MOG-specific T cells, effectively halting and reversing the severity of experimental autoimmune encephalomyelitis (EAE) in animal models without causing systemic immunosuppression.
- Other names
- VHH MHCII-MOG-DEXVHH MHCII-Myelin-DEXVHHMHCII-MOG35-55-DEXVHHMHCII-MOG-35-55-DEXVHHMHCII-MOG 35-55-DEXVHHMHCII-Myelin-DEX
02
Targets
MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on VHHMHCII-MOG-DEX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VHHMHCII-MOG-DEX.